Preventing Heart Failure in People with Diabetes: Guidance for Early Identification and Management

Prof. Busui is Professor and Chief of the Division of Endocrinology, Diabetes and Clinical Nutrition, Director of the Harold Schnitzer Diabetes Health Center, and the Jordan Schnitzer Endowed Chair in Diabetes at the Oregon Health and Science University (OHSU).  She is also the 2023 President for Medicine and Science of the American Diabetes Association (ADA), Professor Emeritus at University of Michigan and an internationally recognized leader in the field of diabetes and diabetes complications.

Her research interests involve chronic complications of diabetes, including diabetic neuropathy, diabetic foot complications, diabetic kidney disease, heart failure, cardiovascular disease, as well as use of novel technologies for diabetes management.  Prof. Busui has published more than 300 peer-reviewed manuscripts and 28 book chapters.  She received awards for her research and advancement of diabetes care from many organisations including the ADA, European Association for the Study of Diabetes (EASD), Fulbright Foundation, Harvard Medical School, Romanian Diabetes Society and the University of Michigan.

Research grant support from NIDDK, Breakthrough T1D ( former JDRF), Lexicon Pharma, Novo Nordisk and Medtronic.  Consulting fees from Bayer, Biogen, Lexicon Pharma, Novo Nordisk and Roche.

Prof. Subodh Verma is a cardiac surgeon-scientist, full professor, and the Canada Research Chair in Cardiovascular Surgery. He is a Fellow of the Canadian Academy of Health Sciences, a past member of the Royal Society of Canada College of New Scholars, Artists and Scientists, and a past recipient of the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery.  Prof. Verma has been a Clarivate Highly Cited Researcher in Clinical Medicine since 2022 (Google Scholar h-index 133 in March 2025) and was bestowed the University of Calgary Cumming School Medicine Alumnus of Distinction Award for Research in 2023.  He is the Editor-in-Chief of Current Opinion in Cardiology, an Associate Editor of the Journal of Thoracic and Cardiovascular Surgery and the European Journal of Heart Failure, an Editorial Consultant for JACC and the current Scientific Program Committee Chair for the Canadian Society of Cardiac Surgeons.

Prof. Verma has actively contributed to Canadian and American clinical practice guidelines, and he had/has leadership roles in numerous contemporary global heart failure, cardiometabolic disease, and atherosclerosis trials.  Prof. Verma founded the CardioLink platform in 2015 that united cardiac surgeons from across Canada to conduct robust clinical trials to better inform on surgical decision-making pathways.  He also leads a dynamic translational research team that leverages pre-clinical disease models and clinical trial-derived data to identify novel mediators of cardiometabolic diseases.

Prof. Verma holds a Tier 1 Canada Research Chair in Cardiovascular Surgery; and reports receiving grants and/or research support and/or speaking honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Canadian Heart Research Centre, Canadian Medical and Surgical Knowledge Translation Research Group, Eli Lilly, HLS Therapeutics, Humber River Health, Janssen, Merck, Novartis, Novo Nordisk, Pfizer, PhaseBio, S & L Solutions Event Management Inc, Sanofi, and Sun Pharma. He is the President of the Canadian Medical and Surgical Knowledge Translation Research Group, a federally incorporated not-for-profit physician organization.

Prof. James Januzzi is currently the Adoph Hutter Professor of Medicine at Harvard Medical School and Chief Scientific Officer and Gibson Chair at the Baim Institute for Clinical Research.  He is a clinician, teacher, experienced clinical researcher and clinical trialist.  Prof. Januzzi’s research work has contributed greatly to the understanding of cardiac biomarker testing, and his studies have set international standards for use in diagnosis, prognosis, and management of patients suffering from heart failure and acute coronary syndromes. He has chaired or participated in numerous committees for trials focused on drug development for heart failure, coronary artery disease and diabetes mellitus.

Prof. Januzzi is among the world’s top 1% most cited researchers, having published more than 900 manuscripts, book chapters, and review articles and he is Deputy Editor at the Journal of the American College of Cardiology.

Grant support from Abbott Diagnostics, AstraZeneca, BMS, HeartFlow, and Novartis.  Consulting income from Abbott Diagnostics, Beckman-Coulter, Janssen, Novartis, Prevencio, Quidel, and Roche Diagnostics.  Equity: Imbria Pharma and JanaCare.  Ongoing clinical endpoint committees/data safety monitoring boards for Abbott, AbbVie, Amgen, CVRx, Medtronic, Pfizer, and Roche Diagnostics.

Prof. Huelsmann is a Clinical Senior Lecturer at the Medical University of Vienna, He leads the heart failure outpatient department and is head of their Scientific Heart Failure Group, former Chair of the Austrian Heart Failure Group, and is the co-founder of the Austrian Working Group for Heart Failure.  Prof. Huelsmann’s current research focus is on heart failure and diabetes and has been involved in large-scale clinical trials. He has co-authored > 300 publications and is a fellow of the Heart Failure Association and the European Society of Cardiology.

Scientific support, honoraria for consultancy and presentations from Roche Diagnostics.

Assoc. Prof. Pandey is an Associate Professor in the Department of Internal Medicine in the Division of Cardiology and the Division of Geriatric Medicine, at UT Southwestern Medical Center.  He is the Medical Director of the heart failure with preserved ejection fraction (HFpEF) program and the Principal Investigator in the Cardiometabolic Research Unit.  He is also the Associate Program Director for Internal Medicine Residency Research, and is an attending physician in cardiology and echocardiology.

His clinical interests include HFpEF and preventive cardiology, particularly the prevention and management of heart failure in older adults.  Assoc. Prof. Pandey has received numerous awards for his contributions to cardiovascular research from the American Heart Association (AHA), the American Geriatrics Society, and the American College of Cardiology, including the including the 2019-20 Elizabeth Barrett-Connor Research Award from the AHA.  He was named a Texas Health Resources Clinical Scholar in 2018, after developing the machine learning-based risk prediction tool, WATCH‐DM risk score, to identify high risk of heart failure in patients with diabetes.  He is also a member of the AHA, serving on several committees, including the Scientific Sessions Planning Committee and the Epidemiology Early Career Committee.  He’s co-authored over 400 peer-reviewed publications and has a h-index of 65.

Research support from the National Institute on Aging GEMSSTAR Grant (1R03AG067960-01), the National Institute on Minority Health and Disparities (R01MD017529), and the National Institute of Heart, Lung, and Blood Institute (R21HL169708).  Grant funding (to the institution) from Applied Therapeutics, Gilead Sciences, Ultromics, Myovista, and Roche.  Consultant for and/or received honoraria outside of the present study as an advisor/consultant for Tricog Health Inc, Lilly USA, Rivus, Cytokinetics, Roche Diagnostics, Sarfez Therapeutics, Edwards Lifesciences, Merck, Bayer, Novo Nordisk, Alleviant, Axon Therapies, and has received nonfinancial support from Pfizer and Merck.  Consultant for Palomarin Inc. with stocks compensation.

Emmanuel Cosson, MD PhD, is a Professor of Medicine and Head of two departments at Assistance Publique des Hôpitaux de Paris (AP-HP).  He is also affiliated with Université Sorbonne Paris Nord, Université Paris Cité, INSERM, INRAE, and CNAM.  Prof. Cosson research focuses on Gestational Diabetes mellitus, Diabetes mellitus and pregnancy, Macrovascular complications, Epidemiology, and Type 1 diabetes.  He has authored around 200 peer-reviewed articles and has an h-index of 43.  Prof. Cosson has also held positions in the French-speaking Society of Diabetes (SFD), the European Association for the Study of Diabetes (EASD), and the Diabetes Pregnancy Study Group (DPSG) of the EASD.

Grants, consulting fees, honoraria for lectures and formation, support for attending meetings, and (co)investigating in researches from Abbott, AlphaDiab, Amgen, AstraZeneca, Asdia, Bayer, Boehringer Ingelheim, Diabeloop, Dexcom, Insulet, DiappyMed, Lilly, LVL medical, NeuTigers, Medtronic, Novartis, Novo-Nordisk, Roche Diabetes, Roche Diagnostics, TIMKL, Sanofi, Urgo, Vitalaire and ViiV Healthcare (GSK).

Christophe Meune is Professor of Cardiology and Head of the Department of Cardiology at University Hospital Avicenne, Paris, France. His main areas of interest are heart failure, biomarkers and cardiac involvement in the course of systemic diseases, and he has published more than 200 articles to date.  Prof. Meune is a Board Member for the French Society of Cardiology and a member of the Joint Society of Cardiology, Emergency Medicine and Biology for Biomarkers.

Lectures fees from Servier, Novartis, Boehringer Ingelheim and AstraZeneca.  Research Grants from AstraZeneca and Roche Diagnostics.